Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Hedgehog pathway inhibitors and activators act on a signaling route that patterns embryos and tissues. The hedgehog gene emerged from a 1980 Drosophila screen for mutations that alter segment number and polarity. In mammals, Sonic, Indian and Desert hedgehog ligands bind the receptor Patched 1 (PTCH1), which then releases its block on Smoothened. Pathway activity converts glioma-associated oncogene (GLI) proteins into transcriptional activators. Inherited PTCH1 mutations were linked in 1996 to nevoid basal cell carcinoma syndrome. Vismodegib acts at Smoothened, whereas GANT61 blocks GLI-mediated transcription further downstream. Purmorphamine activates the pathway, and JK 184 is listed as a Hedgehog inhibitor. Compounds aimed at the transcription factors are also grouped in the neighboring Gli category.
Hh-Ag1.5 is one of the most potent and selective small-molecule agonists of the Hedgehog pathway, targeting Smoothened (Smo) with an EC50 ~1 nM.
GSA-10 is a potent agonist of the smooth (Smo) receptor, playing a crucial role in mediating Hedgehog (Hh) signaling pathways. This compound exhibits significant osteogenic activity and is valuable in regenerative medicine and research on cancer pathologies. Additionally, GSA-10 can be utilized in studies focused on adipogenesis and fat development, making it a versatile tool in biological research.
